Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Osteoporosis 1Neoplasms 1Musculoskeletal Diseases 1Hyperparathyroidism 1Humoral Hypercalcemia Of Malignancy 1Endocrine System Diseases 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Has results × parathyroid hormone-related peptide (1-36) × Clear all
NCT00580788 2016-02-11

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

University of Pittsburgh

Phase EARLY_PHASE1 Completed
14 enrolled 16 charts
Head & Neck

Humoral Hypercalcemia Of Malignancy, Endocrine System Diseases, Hyperparathyroidism, Musculoskeletal Diseases, Neoplasms, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡